Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small cell lung cancer

Lawaly Maman Manzo, Moudirat Lawaly, Lui YU

Abstract


Aberrant increased expression and activation of receptor tyrosine kinases occur frequently in
human carcinomas. Several small molecules targeting receptor tyrosine kinases, which have
crucial roles in the growth factor signaling that promote tumor progression in various
malignancies, including non-small cell lung cancer (NSCLC), are currently in clinical
development. Therapeutic strategies include inhibition of growth factor tyrosine kinase
function. Drugs of this type include those that target the epidermal growth factor receptor
tyrosine kinase, those that target vascular endothelial growth factor receptors tyrosine kinase
and those that target anaplastic lymphoma receptor tyrosine kinase. In this review we first
discuss the role of receptor tyrosine kinases in human malignancies, and focus on discussing
the potential use of epidermal growth factor receptor tyrosine kinase inhibitors and the
vascular endothelial growth factor receptors tyrosine kinase inhibitors in NSCLC. In addition,
we discuss the contribution of growth factor receptor tyrosine kinase inhibitors to the
clinically observed resistance, and toxicity.

Keywords


NSCLC (Non-small cell lung cancer);tyrosine kinase inhibitor; EGFR(endothelial growth factor receptor);VEGFR (vascular endothelial growthfactor receptor)

Full Text:

PDF


DOI: https://doi.org/10.30750/ijpbr.3.2.10

Refbacks

  • There are currently no refbacks.